

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) July 28, 2022**

---

**MicroVision, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34170**  
(Commission  
File Number)

**91-1600822**  
(I.R.S. Employer  
Identification No.)

**6244 185<sup>th</sup> Avenue NE, Suite 100  
Redmond, Washington 98052**  
(Address of principal executive offices) (Zip code)

**(425) 936-6847**  
Registrant's telephone number, including area code

**Not Applicable**  
(Former name or former address if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
<b>Common stock, par value \$0.001 per share</b>	<b>MVIS</b>	<b>The NASDAQ Stock Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 2.02. Results of Operations and Financial Condition.**

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

On July 28, 2022, MicroVision, Inc. issued a press release announcing its second quarter 2022 results. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

Pursuant to the rules and regulations of the SEC, the attached exhibit is deemed to have been furnished to, but not filed with, the SEC.

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release of MicroVision, Inc. dated July 28, 2022</a>
104	Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MICROVISION, INC.**

By: /s/ Drew G. Markham

Drew G. Markham

*Vice President, General Counsel and Secretary*

Dated: July 28, 2022



### MicroVision Announces Second Quarter 2022 Results

REDMOND, WA / ACCESSWIRE / July 28, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its second quarter 2022 results.

“We are pleased to have announced the launch of our new generation MicroVision MAVIN™ lidar hardware during the second quarter of 2022. In June, we completed another round of track testing showcasing how our product can surpass OEM expectations in new, more complex highway driving scenarios,” said Sumit Sharma, MicroVision’s Chief Executive Officer. “We have had very successful driving demonstrations with OEMs and, as we expand our efforts to show our product and deepen engagement with OEMs, we will continue to highlight the excellence and superiority of our product.”

“I am also pleased to announce that as a result of successful engagement with OEMs and Tier 1s, we expect to start strategic sample sales during the second half of 2022 as previously announced. As we continue working to deliver on our 2022 objectives, we plan to demonstrate in 2023 a drive-by-wire system centered on our lidar hardware and our high-speed highway pilot ADAS software,” continued Sharma.

### Key Financial Highlights for Q2 2022

- Revenue for the second quarter of 2022 was \$0.3 million, compared to \$0.7 million for the second quarter of 2021.
- Net loss for the second quarter of 2022 was \$13.6 million, or \$0.08 per share, which includes \$4.1 million of non-cash, share-based compensation expense, compared to a net loss of \$15.0 million, or \$0.09 per share, which includes \$7.9 million of non-cash, share-based compensation expense, for the second quarter of 2021.
- Adjusted EBITDA for the second quarter of 2022 was negative \$9.2 million, compared to negative \$6.7 million for the second quarter of 2021.
- Cash used in operating activities for the second quarter of 2022 was \$9.7 million, compared to \$6.7 million for the second quarter of 2021.
- The Company ended the second quarter of 2022 with \$92.9 million in cash and cash equivalents including investment securities, compared to \$115.4 million at December 31, 2021. The Company has the ability, at its discretion, to offer and sell just over \$70.0 million of equity securities pursuant to its June 2021 ATM facility.

### Conference Call and Webcast: Q2 2022 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Thursday, July 28, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on July 28, 2022.

---

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at <https://ir.microvision.com/events>. The webcast will be archived on the website for future viewing.

#### **About MicroVision**

MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assistance systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.

For more information, visit the Company's website at [www.microvision.com](http://www.microvision.com), on Facebook at [www.facebook.com/microvisioninc](https://www.facebook.com/microvisioninc), follow MicroVision on Twitter at [@MicroVision](https://twitter.com/MicroVision), and LinkedIn at <https://www.linkedin.com/company/microvision/>.

MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

#### **Non-GAAP information**

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with thenon-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.

MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from itsnon-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

---

MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.

### **Forward-Looking Statements**

Certain statements contained in this release, including the Company's plans regarding product demonstration, product capabilities, and expected sales are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.

**Balance Sheet**  
**(In thousands)**  
(Unaudited)

	June 30, 2022	December 31, 2021
<b>Assets</b>		
Current Assets		
Cash and cash equivalents	\$ 36,964	\$ 82,647
Investment securities, available-for-sale	55,926	32,720
Inventory	1,833	1,780
Other current assets	1,027	2,283
Total current assets	95,750	119,430
Property and equipment, net	3,419	3,026
Operating lease right-of-use asset	5,482	5,577
Restricted cash	1,418	1,092
Intangible assets, net	95	115
Other assets	1,028	985
Total assets	<u>\$ 107,192</u>	<u>\$ 130,225</u>
<b>Liabilities and Shareholders' Equity</b>		
Current Liabilities		
Accounts payable	\$ 1,415	\$ 3,584
Accrued liabilities	1,416	1,170
Contract liabilities	4,601	5,265
Other current liabilities	—	1,181
Current portion of long-term debt	9	392
Current portion of operating lease liability	590	849
Current portion of finance lease obligations	24	21
Total current liabilities	8,055	12,462
Operating lease liability, net of current portion	5,029	4,983
Finance lease obligations, net of current portion	8	26
Total liabilities	<u>13,092</u>	<u>17,471</u>
Commitments and contingencies		
Shareholders' Equity		
Common stock at par value	165	164
Additional paid-in capital	750,311	742,042
Accumulated other comprehensive loss	(178)	(19)
Accumulated deficit	(656,198)	(629,433)
Total shareholders' equity	<u>94,100</u>	<u>112,754</u>
Total liabilities and shareholders' equity	<u>\$ 107,192</u>	<u>\$ 130,225</u>

**MicroVision, Inc.**  
**Statement of Operations**  
(In thousands, except earnings per share data)  
(Unaudited)

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
Product revenue	\$ —	\$ —	\$ —	\$ —
License and royalty revenue	314	746	664	1,225
Total revenue	314	746	664	1,225
Cost of product revenue	18	(31)	22	(36)
Total cost of revenue	18	(31)	22	(36)
Gross margin	296	777	642	1,261
Research and development expense	7,700	7,376	15,293	11,838
Sales, marketing, general and administrative expense	6,265	8,355	12,142	10,602
Total operating expenses	13,965	15,731	27,435	22,440
Loss from operations	(13,669)	(14,954)	(26,793)	(21,179)
Other expense, net	72	(8)	28	(14)
Net loss	\$ (13,597)	\$ (14,962)	\$ (26,765)	\$ (21,193)
Net loss per share - basic and diluted	\$ (0.08)	\$ (0.09)	\$ (0.16)	\$ (0.13)
Weighted-average shares outstanding - basic and diluted	165,238	158,818	164,902	157,136

**MicroVision, Inc.**  
**Reconciliation of GAAP Net Loss to Non-GAAP Measure**  
(In thousands, except earnings per share data)  
(Unaudited)

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
GAAP net loss	\$ (13,597)	\$ (14,962)	\$ (26,765)	\$ (21,193)
Add Interest (net)	(107)	5	(138)	9
Add Income taxes	—	—	—	—
Add Depreciation & amortization	418	366	901	665
Add Share-based compensation expense	4,120	7,897	7,854	9,535
Adjusted EBITDA	\$ (9,166)	\$ (6,694)	\$ (18,148)	\$ (10,984)

---

**Investor Relations Contact**

Jeff Christensen and Matt Kreps  
Darrow Associates Investor Relations  
MVIS@darrowir.com

SOURCE: MicroVision, Inc.